STAT+: All eyes on data on Biogen’s tau therapy

The article highlights ongoing developments in biotech, including discussions on Biogen’s tau therapy for Alzheimer’s at a London meeting, research on daraxonrasib for pancreatic cancer, and U.S. regulatory updates such as HHS guidance on tapering SSRIs and FDA approval of Sanofi’s wearable injector for a myeloma drug.